Edition:
United Kingdom

MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

54.00USD
22 Jan 2018
Change (% chg)

$0.05 (+0.09%)
Prev Close
$53.95
Open
$53.75
Day's High
$54.50
Day's Low
$52.85
Volume
82,734
Avg. Vol
126,380
52-wk High
$54.60
52-wk Low
$10.65

Chart for

About

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializi... (more)

Overall

Beta: --
Market Cap(Mil.): $1,434.94
Shares Outstanding(Mil.): 34.96
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-MyoKardia Inc reports Q3 loss per share $0.42

* MyoKardia Inc reports third quarter 2017 financial results and operational progress

02 Nov 2017

BRIEF-MyoKardia expects to initiate next trial of MYK-491 in DCM patients by year-end

* MyoKardia Inc - ‍next trial of MYK-491 in DCM patients expected to initiate by year-end​

27 Sep 2017

BRIEF-MyoKardia announces pricing of public offering of common stock

* MyoKardia announces pricing of public offering of common stock

09 Aug 2017

BRIEF-MyoKardia announces proposed public offering of common stock

* Commenced a proposed underwritten public offering of 3.5 million shares of its common stock Source text for Eikon: Further company coverage:

07 Aug 2017

MyoKardia hits life high after encouraging heart drug data

Shares of MyoKardia Inc hit a record high on Monday after the company said its experimental drug for an inherited heart disease met the main goal in a small mid-stage study.

07 Aug 2017

MyoKardia hits life high after encouraging heart drug data

Aug 7 Shares of MyoKardia Inc hit a record high on Monday after the company said its experimental drug for an inherited heart disease met the main goal in a small mid-stage study.

07 Aug 2017

BRIEF-Myokardia reports Q2 loss per share $0.41

* Myokardia reports second quarter 2017 financial results and operational progress

07 Aug 2017

Earnings vs. Estimates